What does Zinc PCA do?#
Zinc PCA is a gentle, well-tolerated ingredient often used in serums for blemish-prone skin. It pairs the mineral zinc with PCA, a moisture-binding component skin makes naturally, for a comfortable, clearer-looking complexion.
- Supports a clearer-looking complexion in blemish-prone skin
- PCA is part of skin's own moisture-binding system, so it feels comfortable rather than stripping
- Gentle enough for daily use, morning or evening
How it works
Zinc PCA combines the mineral zinc with PCA (pyrrolidone carboxylic acid), a naturally occurring moisturizing ingredient widely used in skincare. PCA is one of the components skin uses to hold on to water, so it contributes to a comfortable, hydrated feel, while the zinc half is used in skincare for its calming character. It is water-soluble and lightweight, so it layers easily under the rest of a routine.
How to use Zinc PCA#
- Morning or evening — zinc PCA suits either, and nothing in the evidence prefers one.
- After cleansing, onto clean skin, before anything heavier.
- Across the whole face. Keep it out of your eyes, nose and mouth.
- Every day from the start is fine. It is one of the gentler ingredients on the list and needs no easing-in period.
- It is water-soluble and lightweight, so it layers easily under a moisturizer or sunscreen.
- There is no adjustment phase to wait out — no purge, no initial dryness. If anything changes for the worse, that is a reason to stop rather than to push through.
- It sits happily alongside almost everything else in a routine, so it does not need a slot of its own.
- Pat gently into skin rather than rubbing for even distribution.
Discontinue use if unexpected discomfort occurs.
The form you will see it in
Zinc PCA calming serum
- Where it goes
- Before sunscreen
Using Zinc PCA with other ingredients
Pairs well with Zinc PCA
Niacinamide
Works well togetherFrequently formulated together for a clearer, calmer-looking complexion.
What not to use with Zinc PCA
Nothing flagged. None of the ingredients this wiki covers needs to be kept apart from Zinc PCA — check the label of anything not covered here.
Who should avoid Zinc PCA?#
Six situations change whether Zinc PCA suits your skin right now. Each one is either a reason to skip it, a reason to go slowly, or nothing to watch for.
- Maternity & Nursing
- No caution
- Fragile or Sensitive
- No caution
- Recent Facial or Laser
- No caution
- Prone to Redness
- No caution
- Dry or Itchy Patches
- No caution
- Recent Shave or Wax
- No caution
Cosmetic strength limits for Zinc PCA where you live#
| Region | Maximum strength |
|---|---|
| United States | No explicit cap |
| Canada | No explicit cap |
| European Union | 1% (as zinc) |
| Great Britain | 1% (as zinc) |
Where a figure appears, that is the maximum strength allowed or advised for zinc pca in that market — some are set in cosmetics regulation, others are the ceiling a cosmetic safety panel recommends. The rest set no maximum. Either way these are limits, not targets — the right strength for a formula is the formulator's decision.
Products with Zinc PCA#
We may earn a small commission when you buy through these links.
Common questions about Zinc PCA#
When should you apply Zinc PCA?
- Morning or evening — zinc PCA suits either, and nothing in the evidence prefers one.
How often can you use Zinc PCA?
- Daily.
Where do you apply Zinc PCA?
- All over the face. Keep it away from your eyes and lips.
Does Zinc PCA make skin more sensitive to the sun?
- No. Zinc PCA is not flagged as increasing sun sensitivity.
What should you not use with Zinc PCA?
- Nothing flagged. None of the ingredients this wiki covers needs to be kept apart from Zinc PCA — check the label of anything not covered here.
Is there a cosmetic limit for Zinc PCA?
- Only some regions set one. The maximum strength for Zinc PCA in a cosmetic is 1% (as zinc) in the European Union and 1% (as zinc) in Great Britain. No maximum is set in the United States and Canada. A cap is a limit on the rules, not a signal to use more.
Related ingredients#
How we check this#
Everything on this page traces to the sources listed below — regulators' own publications and published studies. Where the evidence does not answer a question, it is left unanswered.
Some sources below are the official product information for prescription medicines — some contain this ingredient at higher strengths, others are cited for how they interact with it. We use them for their safety and handling detail only. A cosmetic product is not one of those medicines and is not intended to treat any condition.
Our review is AI-assisted and is not a named expert's opinion. Last reviewed August 8, 2026.
Think something here is out of date or wrong? Email us at wiki@skinintelligence.ai with your reasoning and where you read it. We read what people send, and we update the page when the sources support it.
Regulators and official bodies · 10
- S13Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast), consolidated text, Annex III entry 24 (as amended by Commission Regulation (EU) 2021/1902 of 29 October 2021, OJ L 387); Annex II (zinc pyrithione); Annex VI entries 30/30a (zinc oxide); Annex IV (CI 77947).
- S14Assimilated Regulation (EC) No 1223/2009 on cosmetic products, Annexes as they apply in the UK — Annex 3 entry 24 (amendment F33), Annex 2 entry 1669 (Pyrithione zinc), Annex 6 entries 30/30a (zinc oxide), Annex 4 entry 144 (CI 77947).
- S1521 CFR 358.710 — Active ingredients for the control of dandruff, seborrheic dermatitis, or psoriasis. Lists pyrithione zinc; zinc PCA absent..
- S1621 CFR 347.10 — Skin protectant active ingredients. Lists zinc acetate 0.1–2 % and zinc oxide 1–25 %; zinc PCA absent..
- S17Zineryt 40 mg + 12 mg powder and solvent for cutaneous solution — Summary of Product Characteristics. Erythromycin-zinc complex containing 40 mg/mL erythromycin and 12 mg/mL zinc acetate dihydrate. A different zinc species; POM..
- S18Isotretinoin (Roaccutane) — Summary of Product Characteristics. Names no zinc species; advises a moisturising cream and lip balm from the start of treatment.
- S19Adapalene/benzoyl peroxide gel (Adawell 0.1 %/2.5 %) — Summary of Product Characteristics, §4.5.
- S20Doxycycline capsules — Summary of Product Characteristics, §4.5: gastrointestinal absorption inhibited by bi- or tri-valent ions including zinc; 2–3 hour separation from such medicinal products or foodstuffs. Oral route..
- S21Lymecycline (Tetralysal 300) — Summary of Product Characteristics, §4.5.
- S26Health Canada. Cosmetic Ingredient Hotlist: List of Ingredients that are Prohibited for Use in Cosmetic Products. No entry for zinc PCA, zinc pidolate, or water-soluble zinc salts..
Studies and references · 22
- S1Kezic S, Kammeyer A, Calkoen F, Fluhr JW, Bos JD. Natural moisturizing factor components in the stratum corneum as biomarkers of filaggrin genotype: evaluation of minimally invasive methods. Br J Dermatol 2009;161(5):1098–104. · PMID 19857209 · doi:10.1111/j.1365-2133.2009.09342.x.
- S2Cosmetic Ingredient Review. Safety Assessment of PCA and Its Salts as Used in Cosmetics (Re-Review, release 18 Aug 2014; Panel meeting 8–9 Sep 2014). Prepared by Monice M. Fiume. Covers PCA, sodium PCA, calcium PCA, magnesium PCA, potassium PCA — not zinc PCA..
- S3Takino Y, Okura F, Kitazawa M, Iwasaki K, Tagami H. Zinc l-pyrrolidone carboxylate inhibits the UVA-induced production of matrix metalloproteinase-1 by in vitro cultured skin fibroblasts, whereas it enhances their collagen synthesis. Int J Cosmet Sci 2012;34(1):23–8. · PMID 21834944 · doi:10.1111/j.1468-2494.2011.00676.x.
- S4Jarrousse V, Castex-Rizzi N, Khammari A, Charveron M, Dréno B. Zinc salts inhibit in vitro Toll-like receptor 2 surface expression by keratinocytes. Eur J Dermatol 2007;17(6):492–6. · PMID 17951128 · doi:10.1684/ejd.2007.0263.
- S5Balato A, Caiazzo G, Di Caprio R, Scala E, Fabbrocini G, Granger C. Exploring Anti-Fungal, Anti-Microbial and Anti-Inflammatory Properties of a Topical Non-Steroidal Barrier Cream in Face and Chest Seborrheic Dermatitis. Dermatol Ther (Heidelb) 2020;10(1):87–98. · PMID 31705438 · PMC6994561.
- S6Dall'Oglio F, Lacarrubba F, Luca M, Boscaglia S, Granger C, Micali G. Clinical and instrumental evaluation of a new topical non-corticosteroid antifungal/anti-inflammatory/antiseborrheic combination cream for the treatment of mild-to-moderate facial seborrheic dermatitis. Clin Cosmet Investig Dermatol 2019;12:103–7. · PMID 30774406 · PMC6354683.
- S7Charoenchaipiyakul K, Rujirawan P, Noppakun N, Chongpison Y, Kumtornrut C. A Randomized Controlled Study of the Efficacy of a Topical Antifungal, Antimicrobial, Anti-Inflammatory, and Antiseborrheic Cream in Treating Mild to Moderate Facial Seborrheic Dermatitis. Dermatol Ther 2025. · doi:10.1155/dth/8887280.
- S8Sitohang IBS, Yahya YF, Simanungkalit R, Adi Winarni DR, Madjid A. Efficacy and Tolerability of Topical Nicotinamide Plus Antibacterial Adhesive Agents and Zinc-Pyrrolidone Carboxylic Acid Versus Placebo as an Adjuvant Treatment for Moderate Acne Vulgaris in Indonesia: A Multicenter, Double-blind, Randomized, Controlled Trial. J Clin Aesthet Dermatol 2020;13(7):43–8. · PMID 32983333 · PMC7492018.
- S9Sitohang IBS, Norawati L, Yenny SW, Kusumawardani A, Murlistyarini S, Setiawan SV, Kekalih A, Riany G, Kerob D. Effectiveness and Safety of a Dermocosmetic Cream as an Adjunct to Adapalene for Mild and Moderate Acne in Indonesia: Results of a Multicenter Randomized Controlled Study. Clin Cosmet Investig Dermatol 2024;17:2287–97. Cream contains zinc gluconate per the primary text. · PMID 39430644 · PMC11490241.
- S10Patel MN, Patel NK, Merja AM, Patnaik S. Clinical Evaluation of the Efficacy, Safety, and In-Use Tolerability of a Diacnemide-Containing Acne Kit (Facial Serum and Cleanser) Regimen for the Synergistic Management of Facial Acne in Adults. Cureus 2024. Zinc PCA is in the cleanser (rinse-off); open-label, no control arm, manufacturer-sponsored. · PMID 39445245.
- S11Ge L, Liu Z, Xu S, Li C, Jin M, Luo Y, Kong Y, Meng J, Zheng G, Gao J, Wang P, Bai W, Na H, Zhou X, Jin Z, Pi L. A Cohort Clinical Study on the Efficacy of Topical Salicylic Acid/Piroctone Olamine Dandruff Pre-Gel and Cleanser in Improving Symptoms of Moderate to Severe Seborrheic Dermatitis of the Scalp. J Cosmet Dermatol 2025. · PMID 39778065.
- S12Visser WI, Kannenberg SM, Prevost A, Khoza N, Pillay L, Wiid KJ, Heydenrych IR. Dermocosmetics in Acne Vulgaris: South African Consensus Recommendations With a Focus on Skin of Colour. J Cosmet Dermatol 2026. · PMID 41689191.
- S22Holland KT, Bojar RA, Cunliffe WJ, Cutcliffe AG, Eady EA, Farooq L, Farrell AM, Gribbon EM, Taylor D. The effect of zinc and erythromycin on the growth of erythromycin-resistant and erythromycin-sensitive isolates of Propionibacterium acnes: an in-vitro study. Br J Dermatol 1992;126(5):505–9. · PMID 1610692.
- S23Stamatiadis D, Bulteau-Portois MC, Mowszowicz I. Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol 1988;119(5):627–32. Zinc sulphate, in vitro. · PMID 3207614.
- S24Iinuma K, Noguchi N, Nakaminami H, Sasatsu M, Nishijima S, Tsuboi I. Susceptibility of Propionibacterium acnes isolated from patients with acne vulgaris to zinc ascorbate and antibiotics. Clin Cosmet Investig Dermatol 2011;4:161–5. Zinc ascorbate — a different species, cited only to exclude. · PMID 22087070.
- S25A randomized, double-blind, pilot study on the efficacy and safety of zinc PCA + 4 % nicotinamide-containing cream versus hydrocortisone 1 % cream in the treatment of facial seborrheic dermatitis. Research report, May–June 2015; n=34. Grey literature: no author of record in the index entry, no journal of publication, indexed only by HERDIN, whose host is tier-capped at 3. Cannot back a quantitative claim..
- S27Gallinger J, Kuhn A, Wessel S, Behm P, Heinecke S, Filbry A, Hillemann L, Rippke F. Depth-dependent hydration dynamics in human skin: Vehicle-controlled efficacy assessment of a functional 10 % urea plus NMF moisturizer by near-infrared confocal spectroscopic imaging (KOSIM IR) and capacitance method complemented by volunteer perception. Skin Res Technol 2022;28(2):342–9. Cited as the comparator standard of evidence, not as evidence for zinc PCA. · PMID 35034387.
- S28Piérard GE, Piérard-Franchimont C. Effect of a topical erythromycin-zinc formulation on sebum delivery. Evaluation by combined photometric-multi-step samplings with Sebutape. Clin Exp Dermatol 1993;18(5):410–3. 4 % erythromycin / 1.2 % zinc acetate. · PMID 8252759.
- S29Rostan EF, DeBuys HV, Madey DL, Pinnell SR. Evidence supporting zinc as an important antioxidant for skin. Int J Dermatol 2002;41(9):606–11. Generic zinc review; cited to show what a zinc PCA claim was actually resting on. · PMID 12358835.
- S30Lang C, Murgia C, Leong M, Tan LW, Perozzi G, Knight D, Ruffin R, Zalewski P. Anti-inflammatory effects of zinc and alterations in zinc transporter mRNA in mouse models of allergic inflammation. Am J Physiol Lung Cell Mol Physiol 2007;292(2):L577–84. Mouse airway model; cited to show what a zinc PCA claim was actually resting on. · PMID 17085522.
- S31PubChem compound record, zinc pidolate. CID 11602214, CAS 15454-75-8, EINECS 239-473-5, C₁₀H₁₂N₂O₆Zn, MW 321.6, InChIKey OWVLYQRCCIEOPF-QHTZZOMLSA-L, IUPAC zinc bis((2S)-5-oxopyrrolidine-2-carboxylate); synonyms include Zinc PCA, zinc pyroglutamate, ZINC PIDOLATE [WHO-DD].
- S32See J, Sitohang IBS, Wong SN, Azizan NZ, Noppakun N, Van TT, Dreno B. The Role of Dermocosmetics in Acne Management: Asian Perspective. Clin Cosmet Investig Dermatol 2026. Cited in slot J only, as the source of the zinc gluconate → "Zinc-PCA" mis-attribution. · PMID 41737949.
